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OBJECTIVE—To estimate, among privately insured youth in the U.S., medical expenditures
associated with diabetes and the difference in medical expenditures between individuals with
insulin-treated diabetes mellitus (ITDM) and with non-ITDM (NITDM).
RESEARCH DESIGN AND METHODS—Using the 2007 MarketScan commercial
claims and encounter database, we analyzed data for 49,356 youth (aged#19 years) who were
continuously enrolled in fee-for-service health plans. Youth with diabetes (cases) were identified
from inpatient, outpatient, and pharmaceutical drug claims. Each case was matched with five
controls (without diabetes) by age (62 years), sex, census region, and urban versus rural resi-
dence. We used regression models to estimate medical expenditures in total and by component
(inpatient, outpatient, and medication).
RESULTS—The predicted mean annual total per-person medical expenditures were $9,061
for youth with diabetes and $1,468 for those without, an excess of $7,593 for those with diabetes;
of which, 43% was for prescription drugs. The predicted mean annual total expenditures were
$9,333 for ITDM youth and $5,683 for NITDM youth, respectively, an excess of $3,650 for those
with ITDM diabetes, of which 59% was for prescription drugs.
CONCLUSIONS—The excess medical expenditures associated with diabetes, ITDM in par-
ticular, among youth are substantial. Our estimates of excess expenditures can be used to assess
the economic burden of diabetes overall and by diabetes treatment mode. Our estimated excess
expenditure for NITDM may be used for evaluating the economic efficiency of interventions
aimed at preventing type 2 diabetes in U.S. youth.
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D iabetes is one of the most prevalentchronic diseases among U.S. youth.In 2001, an estimated 1.8 per 1,000
individuals aged ,20 years in the U.S.
had diabetes (1). An increase in the inci-
dence of type 1 diabetes, the most com-
mon form of diabetes in the young, has
been reported in Europe and the U.S.
(2,3). Furthermore, with increasing obe-
sity rates in the young, type 2 diabetes,
once considered an adult disorder, now
occurs in adolescents, especially in mi-
nority populations (4).
Besides its adverse effects on an individ-
ual’s health and quality-of-life, diabetes also
imposes a staggering financial burden on
the health care system. Numerous studies
have estimated the medical costs of diabe-
tes among adults or for the entire U.S. di-
abetic population (5–7). A few studies
have also estimated the direct medical ex-
penditures of diabetes among children
and adolescents in European countries
(8,9), as has one study in the U.S. (10).
However, the U.S. study was based on a
small sample of hospital patients.
Estimates of the direct medical costs
attributed to diabetes among youth are
essential to assess the financial burden of
the disease and plan for future health care
needs. In addition, because type 2 di-
abetes is potentially preventable (11), es-
timates of medical expenditures are
needed to assess the full economic effect
of programs aimed to prevent type 2 di-
abetes in youth.
Our study’s objectives were to esti-
mate 1) the excess medical expenditures
associated with diabetes, and 2) the differ-
ences inmedical expenditures for individ-
uals with insulin-treated diabetes mellitus
(ITDM) and non-ITDM (NITDM).
RESEARCH DESIGN AND
METHODS
Data source
We analyzed data from the MarketScan
Commercial Claims and Encounters
Database (CCE) (MarketScan Database;
Thompson Medstat, Ann Arbor, MI).
Widely used to estimate the health expen-
ditures of various illnesses—including di-
abetes among adults (6,12,13)—the CCE
database annually compiles fully adjudi-
cated and paid health insurance claims
from more than 100 large employers and
health plans. The claims come from several
million individuals, including employees,
their spouses, and dependents, who are
covered by employer-sponsored private
health insurance (14). The CCE includes
patient-level data on inpatient, outpatient,
and drug claims. All three can be linked
through encrypted and unique enrollee
identifiers (15).
Enrollee health plans are divided into
fee-for-service (FFS) plans and fully or
partially capitated plans. FFS plans in-
clude preferred provider organization
(PPO) plans, exclusive provider orga-
nization plans, point-of-service plans,
consumer-directed health plans, and in-
demnity plans. Fully or partially capitated
plans include health maintenance orga-
nizations and point-of-service plans with
capitation (15).
Study population
We restricted our analyses to 3,366,791
youth aged #19 years who were contin-
uously enrolled in FFS health plans with
prescription drug coverage from 1 January
through 30 December 2007 (Fig. 1). We
limited our analysis to individuals enrolled
in FFS plans because their insurance claims
represent actual payment for the services,
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whereas payment records in capitated
plans often only reflect encounters (15).
We excluded 0.5% of the youth because
ofmissing records for census region (north-
east, midwest, south, and west) or resi-
dence (rural vs. urban).
We identified an individual as having
diabetes if the record showed 1) at least
two outpatient encounters that were at
least 30 days apart, coded for diabetes
as a primary or secondary diagnosis
(16), or 2) at least one inpatient admission
coded for diabetes as a primary or second-
ary diagnosis, and 3) at least one pharma-
ceutical drug claim filled for insulin or
oral hypoglycemic agents, or both. The
requirement for at least two outpatient
encounters protected against inclusion
of youth who were misdiagnosed at the
first encounter and were later determined
not to have diabetes (17). To indicate di-
abetes, we used the ICD-9-CM codes
250.00–250.93, 357.2, 362.0–362.02,
and 366.41 in outpatient and inpatient
claims (12,18) and the Therapeutic Class
Codes of 172, 173, and 174 in drug
claims. We identified 8,226 youth who
had diabetes.
Because the presence of other chronic
conditions could substantially influence
health care expenditures, themodel should
account for these conditions. Among
the 8,226 youth with diabetes, 4.6% had
asthma, the most commonly reported
chronic disease in youth, and we included
data on these individuals. A total of 159
youth (,2%) had one or more of the fol-
lowing uncommon chronic conditions:
congenital heart failure, hemiplegia, lym-
phoma, Down syndrome, autism, leuke-
mia, congenital heart defects, and liver
diseases. Because the number of observa-
tions for each of the uncommon chronic
conditions was too small to produce a re-
liable estimated coefficient for that condi-
tion, we excluded data on these youth.
Remaining in our sample were 8,226
youth with diabetes.
We used bootstrapping to estimate
the SEs of predicted and excess mean
expenditures. Bootstrapping the entire
database of diabetes and without diabetic
youth exceeded our computation capac-
ity, so we used a case-control design to
reduce the sample size. Each youth with
diabetes (case subject) was directly matched
one-to-one with five youth without
diabetes (control subject), on the multiple
variables: age (62 years), sex, U.S. census
region, and residence. For each case, con-
trol subjects were selected from a random-
ized subset of combination of matching
variables without replacements. Each
case-control matched set was identified
as a unique cluster. Our analytic sample
comprised 49,356 youth.
Data limitations precluded us from
conclusively distinguishing type 1 and
type 2 diabetes. We distinguished youth
with diabetes by treatment mode (ITDM
vs. NITDM). Those who had at least one
prescription filled for insulin (Therapeutic
Class Code of 172) were identified as
having ITDM. By use of this method,
we identified 7,556 diabetic youth who
had ITDM. In contrast, remaining in our
sample were 670 individuals with di-
abetes but without insulin prescriptions.
These youth were considered to have
NITDM.
Statistical analysis
We used t tests to assess differences in the
means of sample characteristics and com-
pared youthwith diabetes and those with-
out diabetes and youth with ITDM and
those with NITDM.
Estimation of expenditures: comparing
youth with and without diabetes. We
used a two-part model (19,20) to estimate
the excess medical expenditures associ-
ated with diabetes in total and by compo-
nent: outpatient, inpatient, and drug
expenditures. The two-part model was
used because a large proportion of the
nondiabetic youth had nomedical expendi-
tures, and among those who did, the med-
ical expenditures were right-skewed (19).
In the first part of the two-part model,
we estimated the probability that an in-
dividual would have a positive medical
expenditure. We used a generalized esti-
mating equation (GEE) with logit link and
binomial distribution and accounted for
the dependence within matched sets
(clusters). In the second part, we esti-
mated the level of expenditures among
youth who had positive expenditures.
Here, we used a GEE model with log
link and g distribution, again accounting
for the dependence within the cluster. Be-
cause health plan type (PPO versus non-
PPO) and the presence of asthmawere not
used in the case-control matching, we in-
cluded both as covariates. The main ex-
posure was a diagnosis of diabetes.
We calculated model-based predicted
marginal medical expenditures by diabetes
status. To estimate the predicted mar-
ginal medical expenditures associated
with diabetes, the diabetes indicator vari-
able was first set to 1 for all individuals and
then again to 0 for all individuals. All
other variables remained at their original
Figure 1—Selection of study sample. DM, diabetes mellitus.
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values. For both indicator sets, individual
predicted values were calculated, and the
predictions were averaged over all obser-
vations. The difference in the predicted
mean expenditure between youth with
and without diabetes was the excess-
predicted expenditure associated with di-
abetes. We used 1,000 nonparametric
bootstrap replications of clusters to cal-
culate the SE of predicted and excess
expenditures (21).
Estimation of expenditures: comparing
youth by diabetes treatment mode. To
estimate medical expenditures in total
and by component associated with each
of the two diabetes treatment modes
(ITDM and NITDM), we used a two-part
model to estimate the inpatient expen-
ditures and only the second part of the
two-part model to estimate the total, out-
patient, and drug expenditures.
Estimation of the first part of the two-
part model was not needed for estimating
the total, outpatient, and drug expendi-
tures because all youth with diabetes had
positive expenditures for those compo-
nents. In estimating the inpatient expen-
ditures, similar to the model used for
estimating expenditures for youth with or
without diabetes in the first part, we used a
logistic regression model to estimate the
probability of a youth having a nonzero
inpatient expenditure.
In the second part, we used a gener-
alized linear model with log link and a g
distribution to estimate the expenditures
among youth who had positive inpatient
expenditures. In estimating the total, out-
patient, and drug expenditures, we used a
generalized linear model with log link and
g distribution among all youth with dia-
betes.
For all models, we included age, sex,
U.S. census region, residence, health plan
type (PPO vs. non-PPO), and the pres-
ence of asthma as covariates. The pre-
dicted mean medical expenditures for
youth with ITDM and with NITDM and
predicted excess expenditure associated
with ITDM were estimated in the same
way as for youth with diabetes versus
without diabetes. We used 1,000 non-
parametric bootstrap replications to cal-
culate the SE of predicted and excess
expenditures.
Using the model-based predicted
mean annual expenditures, we calculated
ratios of per capita annual medical ex-
penditures in total and by component:
expenditures for youth with diabetes di-
vided by expenditures for those without
diabetes, and expenditures for youth with
ITDM divided by expenditures for those
with NITDM.
All analyses were performed using
STATA 10.1 software (StataCorp, College
Station, TX). We considered results sig-
nificant at P , 0.05.
RESULTS
Characteristics of the study
population
Of the 49,356 youth, 15.2% had no med-
ical expenditures, 18.0%had no outpatient
expenditures, 95.9% had no inpatient ex-
penditures, and 35.1% had no prescription
drug expenses. Of those identified with
diabetes, 91.9%were taking insulin, alone
or combined with oral hypoglycemic
agents, and 84.0% had not been hospital-
ized during the year.
The characteristics of the study pop-
ulation by diabetes status and treatment
mode are summarized in Table 1. Among
youth with diabetes, those with ITDM
were significantly younger (12.7 vs. 14.8
years; P, 0.05) and less likely to be girls
(47.7% vs. 67.5%; P , 0.05). Compared
with youth with NITDM, those with
ITDM were more likely to be from the
west (13.3% vs. 16.7%; P , 0.05) and
less likely to be from the south (52.1%
vs. 42.8%; P , 0.05). The percentage of
youth with asthma was significantly
greater among those with NITDM than
among those with ITDM (9.7% vs.
4.1%; P , 0.05).
Medical expenditures associated
with diabetes
The predicted mean annual total medical
expenditure was $9,061 for youth with
diabetes and $1,468 for youth without
diabetes, an excess of $7,593 among di-
abetic youth (P, 0.05; Table 2). The out-
patient, inpatient, and drug expenditures
were all significantly greater for diabetic
youth than those without (P, 0.05). Re-
gardless of diabetes status, outpatient
expenditures (43 and 66% for those
with or without diabetes, respectively) ac-
counted for the largest share of the total
expenditures, followed by prescription
drugs (39 and 19%, respectively) and
inpatient expenditures (18 and 15%,
respectively). However, excess expendi-
tures on prescription drugs accounted
for the largest proportion of the excess
total expenditures ($3,228; 43%), fol-
lowed by excess expenditures on outpa-
tient care ($2,970; 39%) and inpatient
care ($1,406; 19%). For youth with dia-
betes, the predicted mean expenditures
were $811 on diabetes supplies and
$1,688 on medications (data not shown).
Medical expenditures for youth
with ITDM and NITDM
The predicted mean total medical expen-
diture was $9,333 for youth with ITDM
and $5,683 for those with NITDM, an
excess of $3,650 (P , 0.05) for youth
with ITDM (Table 2). The three compo-
nent expenditures were all significantly
greater for youth with ITDM than for
youth with NITDM (P , 0.05). Regard-
less of treatment mode, the outpatient
expenditures comprised the largest share
of total expenditure (43 and 58%, respec-
tively, for ITDM and NITDM youth), fol-
lowed by prescription drugs (39 and
26%, respectively) and inpatient expen-
ditures (18 and 17%, respectively). How-
ever, of the predicted excess total medical
expenditure for youthwith ITDM,predicted
Table 1—Characteristics of study population by diabetes status and diabetes
treatment mode
Variables
Cases Controls Diabetes treatment mode
With diabetes Without diabetes ITDM NITDM
n 8,226 41,130 7,556 670
Mean age, years 12.87 (0.05) 12.78 (0.02) 12.70* (0.05) 14.84* (0.12)
Sex: girls, % 49.28 (0.55) 49.28 (0.25) 47.67* (0.57) 67.46* (1.81)
Census region, %
Midwest 30.46 (0.51) 30.46 (0.23) 30.72* (0.53) 27.61 (1.73)
South 43.54 (0.55) 43.54 (0.24) 42.79* (0.57) 52.09* (1.93)
West 16.42 (0.41) 16.42(0.18) 16.70*(0.43) 13.28*(1.31)
Urban residence, % 80.18 (0.44) 80.18 (0.20) 80.40 (0.46) 77.76 (1.61)
Non-PPO health plan, % 24.53 (0.47) 24.86 (0.21) 24.60 (0.50) 23.73 (1.64)
Asthma, % 4.55 (0.23) 4.36 (0.10) 4.09* (0.23) 9.70* (1.14)
Data are presented as mean (SE). *Statistically significant (P , 0.05) comparison of means between groups
(youth with diabetes versus without diabetes, or ITDM versus NITDM).
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excess expenditures on prescription drugs
accounted for the largest proportion
($2,137; 59%), followed by expenditures
on inpatient ($712; 20%) and outpatient
care ($697; 19%). The expenditure on di-
abetes supplies was $863 for ITDM and
$82 for NITDM youth, and the expendi-
ture for diabetes medication was $1,826
for ITDM and $228 for NITDM youth
(data not shown).
CONCLUSIONS—The medical ex-
penditures associated with diabetes in
general and by diabetes treatment mode
among U.S. youth are less known. Using
administrative claims data from .3 mil-
lion youth, we estimated that the excess
mean total medical expenditure asso-
ciated with diabetes among youth was
$7,593 per year. Estimated mean annual
total medical expenditures were $9,333
for ITDM youth and $5,683 for NITDM
youth, an excess of $3,650 for those with
ITDM. Our ITDM group included all
youth with type 1 diabetes but probably
also some with type 2. Youth with
NITDM most likely have type 2 diabetes
(4,22–25), therefore, our estimated med-
ical expenditures for NITDM youth likely
represent a lower bound for youth with
type 2 diabetes receiving medications in
the U.S.
We found that excess expenditures
on prescription drugs contributed the
most to the total excess medical expendi-
tures associated with diabetes in youth.
This contrasts with findings for the entire
diabetic population, where hospitalization
or inpatient expenditures contributed the
most (5,8). However, our results of health
care spending across components are con-
sistent with the estimates for a closely com-
parable age group (#14 years) in Sweden
(8). Our relatively large expenditure on
prescription drugs was mainly driven
by a greater proportion of diabetic youth
who required treatment with insulin, thus
their greater expenses on insulin and di-
abetes supplies. This is consistent with
findings in Sweden (8).
We found that among diabetic youth
and regardless of treatment mode, the
drug expenses are mainly driven by the
expenses for medications. The expenses
for diabetic supplies are likely under-
estimated because not all health insur-
ance plans cover the costs of the diabetes
supplies.
Our estimated level of per capita total
medical expenditure attributable to di-
abetes of $7,593 is greater than a corre-
sponding per capita estimate of $6,649
for the entire U.S. diabetic population in
2007 (5). Our estimated total medical ex-
penditures ratio of those with diabetes
compared with those without diabetes is
also larger than that estimated for adults,
which ranges from 2 to 5 (5,7). However,
our estimated total medical expenditures
ratio is lower than in the previously men-
tioned Swedish study (8). Our results are
generally consistent with what has been
previously reported: excess expenditure
is higher in younger age groups, and the
expenditures ratio between persons with
or without diabetes tends to decrease with
age (7,8). The higher excess expenditure
in younger age groups may have been
driven by costs for specialist visits, medi-
cations, and diabetes testing supplies (8).
The higher medical expenditures ratio for
youth may also have been driven by rela-
tively lower medical expenditures for
youth without diabetes than that for older
populations without diabetes.
Our study has several limitations.
First, our medical claim data are from
enrollees in employer-sponsored health
plans and without uncommon chronic
conditions. The study population did not
include individuals without health insur-
ance coverage, those on Medicaid, and
those identified with uncommon chronic
conditions. Hence, the results may not be
generalized to the U.S. youth population.
Our sample only represents those en-
rolled in FFS plans and, therefore, may
not reflect medical expenditures for those
enrolled in capitated plans.
Second, the accuracy of our estimates
is subject to diagnostic coding errors;
however, the MarketScan database under-
goes rigorous data quality checks, and less
than 1% of all claims could not be verified
(14).
Last, we could not estimate the excess
expenditures by diabetes type because the
MarketScan database does not provide
sufficient information to differentiate type
1 from type 2 diabetes. We were also
unable to correctly identify diabetic youth
who were treated with diet and exercise
only; therefore, our sample does not in-
clude this population.
Our study showed that the excess
medical expenditures associated with di-
abetes in youth were substantial. Our
estimates associated with diabetes (both
ITDM and NITDM) can be used to esti-
mate the economic burden of diabetes in
youth in the U.S. The estimates of expen-
diture for NITDMcan also serve as a lower
bound to evaluate the benefits of type 2
diabetes prevention programs. Future re-
search on estimation of costs among
youth with diabetes not on medications
would provide additional insights into
the expenditure associated with diabetes
among youth.
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Table 2—Predicted mean annual medical expenditures (U.S. $) in 2007 for U.S. youth by
diabetes status and treatment mode*
Diabetes status and treatment mode
Expenditure models
Total Outpatient Inpatient Drug
Diabetes vs. without diabetes†
With diabetes 9,061 (135) 3,939 (59) 1,628 (99) 3,505 (45)
Without diabetes 1,468 (29) 969 (21) 222 (16) 277 (6)
Excess: diabetes 7,593 (138) 2,970 (63) 1,406 (89) 3,228 (45)
Ratio 6.2 4.1 7.3 12.7
ITDM vs. NITDM‡
ITDM 9,333 (132) 3,997 (57) 1,688 (89) 3,629 (44)
NITDM 5,683 (487) 3,300 (287) 976 (244) 1,492 (150)
Excess: ITDM 3,650 (509) 697 (295) 712 (256) 2,137 (157)
Ratio 1.6 1.2 1.7 2.4
*All excess expenditures are statistically significant (P, 0.05). Values in parentheses are bootstrap SE using
1,000 replications. Because of separate estimations of component models and rounding of values, the sum of
predicted medical expenditures across the components do not necessarily sum to total expenditures. †Co-
variates in all models are: health plan (PPO vs. non-PPO) and presence of asthma. ‡Covariates in all models
are: age, sex, census region, residence, health plan, and presence of asthma. Reference groups were as follows:
boys, northeast region, rural residence, PPO health plan, and without asthma.
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